First, the CIMA-Q cohort did not include tau and amyloid brain imaging, which means we cannot confirm whether the cognitive symptoms observed in participants with SCD and MCI are due to underlying Alzheimer's disease pathology, nor can we evaluate protein-based models. The gene discussed is MAPT; the disease is Alzheimer disease.